Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2022

Genmab — Juli 2022

Planlagt Fastgjort Låst Flyttet Genmab
808 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #105

    Aktier/middag: C25 tynges af makrousikkerhed - SAS i tocifret fald https://www.proinvestor.com/investornyt/845961/aktier-middag-c25-tynges-af-makrousikkerhed-sas-i-tocifret-fald

    1 Reply Last reply
    0
    • D Offline
      D Offline
      deleted-user
      wrote on sidst redigeret af
      #106

      Det ender med, at Helge må invitere på romkugler og Bjørnebryg i baghaven....

      1 Reply Last reply
      0
      • P Offline
        P Offline
        ProinvestorNEWS
        wrote on sidst redigeret af
        #107

        😄

        1 Reply Last reply
        0
        • S Offline
          S Offline
          Sukkeralf
          wrote on sidst redigeret af
          #108

          Tror ikke der har været linket til denne:

          1 Reply Last reply
          0
          • S Offline
            S Offline
            Sukkeralf
            wrote on sidst redigeret af
            #109

            Just a moment...

            favicon

            (firstwordpharma.com)

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #110

              Johnson & Johnson's mAb looks set to win on all fronts over the next few years in the multiple myeloma market.

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #111

                Det bliver spændende:

                1 Reply Last reply
                0
                • S Offline
                  S Offline
                  Sukkeralf
                  wrote on sidst redigeret af
                  #112

                  Data from Johnson & Johnson's Phase II LYNX study, which due to readout late this year or in early 2023, could provide some answers. This trial is evaluating Darzalex in combination with Kyprolis (carfilzomib) and dexamethasone (Kd), versus Kd alone, in approximately 230 patients that have received one to three prior lines of therapy, one of which contained Darzalex.

                  1 Reply Last reply
                  0
                  • S Offline
                    S Offline
                    Sukkeralf
                    wrote on sidst redigeret af
                    #113

                    Feedback from our poll overwhelmingly supports the assertion that MM patients can be re-treated with Darzalex, on the assumption that there has been an extended break in exposure to the drug. All 30 specialists said they are comfortable re-treating patients with Darzalex in these circumstances, with 50% of respondents describing themselves as 'very' comfortable with this approach and 37% as 'extremely' comfortable.

                    1 Reply Last reply
                    0
                    • S Offline
                      S Offline
                      Sukkeralf
                      wrote on sidst redigeret af
                      #114

                      Ligeledes spændende:

                      1 Reply Last reply
                      0
                      • S Offline
                        S Offline
                        Sukkeralf
                        wrote on sidst redigeret af
                        #115

                        oncurrently, Darzalex is also being evaluated as a potential maintenance treatment for MM. In the Phase III AURIGA trial, the combination of Darzalex plus Revlimid (lenalidomide) versus Revlimid alone is being studied as maintenance treatment in approximately 214 patients with newly diagnosed MM who are MRD positive following high-dose therapy (HDT) and autologous stem cell transplant (ASCT).

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #116

                          The primary outcome measure is percentage of patients achieving MRD-negative status with results anticipated next year.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #117

                            A third of the physicians said they are extremely confident Darzalex will become an established maintenance therapy for MM based on its known clinical profile, with a further 53% describing themselves as being very confident of this outcome.

                            1 Reply Last reply
                            0
                            • S Offline
                              S Offline
                              Sukkeralf
                              wrote on sidst redigeret af
                              #118

                              Let us hope they are right 🙂

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #119

                                The position of Darzalex as both a key growth driver for Johnson & Johnson and anchor point for its longer-term ambitions in the MM market look set to remain undiminished.

                                1 Reply Last reply
                                0
                                • nohopeN Offline
                                  nohopeN Offline
                                  nohope
                                  wrote on sidst redigeret af
                                  #120

                                  Hope is not a strategy...

                                  1 Reply Last reply
                                  0
                                  • D Offline
                                    D Offline
                                    deleted-user
                                    wrote on sidst redigeret af
                                    #121

                                    Det er vist heller ikke sukkeralf, der udstikker strategien .... det er JnJ og den er ikke baseret på håb 😄

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #122

                                      great survey! looking forward to that maintenance data! many have been sceptical about maintenance (and about re-treating actually) so I would think that could still raise peak sales targets if data is good

                                      1 Reply Last reply
                                      0
                                      • S Offline
                                        S Offline
                                        Sukkeralf
                                        wrote on sidst redigeret af
                                        #123

                                        Yes - otherwise we hope HexaBody CD38 can do the job

                                        1 Reply Last reply
                                        0
                                        • S Offline
                                          S Offline
                                          Sukkeralf
                                          wrote on sidst redigeret af
                                          #124

                                          ......yet another hope nohope 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper